Journal article

Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds

Peter Wong, Nathan Lawrentschuk, Damien M Bolton

Current Opinion in Urology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2009

DOI: 10.1097/MOU.0b013e328316c357

Citation metrics

18Web of Science
19Scopus
18Dimensions

Keywords

Sexual Function
Benign Prostatic Hypertrophy
Type-5 Inhibitors
Adrenergic Alpha-Antagonists
Prostatic Hyperplasia
Phosphodiesterase 5 Inhibitors
Urinary Tract
5-Alpha Reductase Inhibitors
5-Alpha-Reductase Inhibitors
Life Sciences & Biomedicine
Phosphodiesterase Inhibitors
5-Alpha Reductase
Finasteride
Treatment Options
Male
Pde5 Inhibitors
Urinary-Tract Symptoms
Science & Technology
Urology & Nephrology
Lower Urinary Tract Symptoms
Sildenafil Citrate
Humans
Drug-Therapy
Erectile Dysfunction